AMAnastasia A. Makushina

Anastasia A. Makushina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anastasia A. Makushina has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gastroesophageal Reflux Disease and Barrett's Esophagus: Optimization of Patient Management and Cancer Prevention Measures (Literature Review and Resolution of the Expert Council of the Russian Gastroenterolog

    by V. T. Ivashkin, I. V. Maev, A. S. Trukhmanov, T. L. Lapina, D. N. Andreev, O. P. Alexeeva, S. A. Alekseenko, A. Yu. Baranovsky, O. V. Zayratyants, O. Yu. Zolnikova, et al.

    Aim: to summarize current clinical guidelines and meta-analyses data, and to present the main statements of the Expert Council of the Russian Gastroenterological Association regarding the optimization of endoscopic diagnosis, morphological verification, pharmacotherapy, and management strategies for patients with gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Key points. In the Russian Federation, GERD is a highly prevalent disease: according to a meta-analysis involving over 30,000 individuals, the frequency of heartburn and/or regurgitation occurring once a week or more is 25 %. Proton pump inhibitors (PPIs) represent the cornerstone drug class for the treatment of GERD. Rebamipide targets altered epithelial permeability and mucosal inflammation. Combination therapy with PPIs and rebamipide improves symptoms in patients with non-erosive reflux disease, leading to positive morphological changes in the esophageal mucosa and improved control of nocturnal esophageal acid exposure. Ursodeoxycholic acid (UDCA) may be added to GERD therapy in the presence of biliary reflux or reflux gastritis. The clinical significance of GERD is determined not only by its high prevalence, chronic relapsing course, and impaired quality of life, but also by its precancerous potential. In individuals with GERD, the prevalence of Barrett’s esophagus is approximately 7 %, while the incidence of adenocarcinoma and/or high-grade dysplasia in the presence of low-grade dysplasia is 1.73% annually. Risk factors for the development of Barrett’s esophagus include male sex, age over 50 years, frequent GERD symptoms, tobacco smoking, obesity, and a positive family history. The management of patients with Barrett’s esophagus requires strict adherence to endoscopic and histological diagnostic protocols. Long-term PPI pharmacotherapy remains the standard of chemoprevention against neoplastic progression, demonstrating superiority over surgical treatment. Timely screening of high-risk individuals and adherence to endoscopic surveillance intervals enable the detection of dysplasia and esophageal adenocarcinoma at early, treatable stages. Conclusion. The Expert Council members proposed algorithms for the treatment of acute GERD exacerbation and maintenance therapy, as well as for the diagnosis and surveillance of patients with Barrett’s esophagus, taking into account current evidence and principles of evidence-based medicine. The literature review and the proposed algorithms aim to provide informational support for general practitioners, internists, gastroenterologists, and endoscopists in order to improve the quality of healthcare delivery and ensure effective prevention of esophageal adenocarcinoma.

  • Open Access

    Comparison of the Efficacy of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers in Achieving and Maintaining Endoscopic Remission in Erosive Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

    by P. G. Ermishina, A. S. Trukhmanov, A. A. Makushina, O. A. Storonova, A. V. Paraskevova, V. T. Ivashkin, П. Г. Ермишина, А. С. Трухманов, А. А. Макушина, О. А. Сторонова, et al.

    Aim: to compare the efficacy of proton pump inhibitors and potassium-competitive acid blockers (P-CABs) in achieving and maintaining endoscopic remission in erosive gastroesophageal reflux disease. Materials and methods. A systematic literature search using specified keywords was performed through June 17, 2025, in the MEDLINE/PubMed, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases. Results. A total of 2,758 patients from six studies were included in this systematic review and meta-analysis. The meta-analysis showed a trend in favor of P-CABs at week 4 of therapy, although the difference was not statistically significant: OR = 1.29; 95% CI: 0.93–1.80; p = 0.13. At week 8, P-CABs demonstrated a statistically significant advantage over proton pump inhibitors in achieving endoscopic remission: OR = 1.92; 95% CI: 1.39–2.64; p < 0.0001. P-CABs were also more effective than proton pump inhibitors in maintaining endoscopic remission: OR = 1.77; 95% CI: 1.42–2.21; p < 0.00001. Heterogeneity across these analyses was low ( I 2 = 0–4 %). Conclusion. P-CABs are an effective alternative to proton pump inhibitors for achieving and maintaining endoscopic remission in patients with erosive gastroesophageal reflux disease. Further prospective studies are needed to optimise treatment regimens, assess long-term safety, and compare the efficacy of different agents within the P-CAB class.


  • Control of nocturnal gastroesophageal reflux in non-erosive reflux disease with proton pump inhibitor and rebamipide combination therapy: results of a prospective randomized study

    by Anastasia A. Makushina, Aleksandr S. Trukhmanov, Olga A. Storonova, Anna V. Paraskevova, Polina G. Ermishina, Victoria A. Mironova, Vladimir T. Ivashkin

    Objective. To evaluate the efficacy of combination therapy with a proton pump inhibitor (PPI) and rebamipide compared to PPI monotherapy in controlling nocturnal gastroesophageal reflux (GER) in patients with non-erosive reflux disease (NERD), based on 24-hour pH-impedance monitoring in the nocturnal supine position. Patients and methods. This prospective randomized study included 39 patients with NERD. All patients were divided into two groups: the study group (n = 22) received omeprazole 20 mg/day and rebamipide 300 mg/day; the comparison group (n = 17) received omeprazole 20 mg/day. The duration of treatment was 4 weeks. Efficacy was assessed functionally using 24-hour pH-impedance monitoring before and after treatment, with analysis of nocturnal parameters in the supine position. Results. In the study group, the duration of the longest nocturnal GER episode decreased by 78% (p = 0.016), and there was a notable positive trend in the percentage of time with pH 5 minutes (p = 0.039) and a trend toward a difference in the change in the percentage of time with pH <4 (p = 0.051). Conclusion. Combination therapy with rebamipide and PPI demonstrated both statistically significant and clinically meaningful superiority over PPI monotherapy in controlling nocturnal GER in patients with NERD, as evidenced by a substantial reduction in acid exposure and the number of pathologically prolonged reflux episodes in the supine position. These findings support the inclusion of rebamipide in the treatment regimen for NERD to improve control of nocturnal symptoms. Key words: proton pump inhibitors, rebamipide, non-erosive reflux disease, epithelial protective therapy


  • Open Access

    Clinical and morphological features and functional parameters in patients with gastroesophageal reflux disease and Barrett's esophagus

    by A S Trukhmanov, A V Paraskevova, O A Storonova, A B Ponomarev, A A Makushina, V T Ivashkin

    Aim. To develop a treatment strategy based on the analysis of clinical manifestations and the results of morphofunctional diagnostics for patients with gastroesophageal reflux disease (GERD) aimed at preventing the development and progression of intestinal metaplasia (IM) of the esophageal epithelium. Materials and methods. The study included 50 subjects diagnosed with GERD. After esophagogastroduodenoscopy with biopsy and subsequent morphological examination of the esophageal mucosa, two groups were formed: patients with GERD complicated by IM, also known as Barrett’s esophagus (n = 19), patients with GERD without IM (n = 31). All participants underwent high-resolution esophageal manometry and 24-hour impedance pH monitoring. Results. The study found that in patients with GERD complicated by IM, complaints of intense heartburn and difficulty swallowing occurred more often than in patients with GERD without IM. According to manometry, the resting pressure of the lower esophageal sphincter in patients with GERD and IM (15.1 [1.3; 36.4] mmHg) was lower than in patients with GERD without IM (20.3 [5.5; 42.1] mmHg). This difference was statistically significant (p = 0.002). In patients with GERD and IM, esophageal motility is less effective; this was translated in a decrease in the distal contractile integral of the esophagus to 276.5 [0.2; 567.7] mmHg × s × cm, while in patients with GERD without IM, it was much higher: 942.5 [47.3; 3759.7] mmHg × s × cm. Difficulties in swallowing were associated with a reduced effectiveness of esophageal motility. In patients with GERD complicated by IM, more acid gastroesophageal refluxes were observed compared to patients without IM (72.5 [53.5; 91.5] vs 54.2 [29.9; 78.3]; p = 0.036). They also have a greater percentage of time with pH 4.0 in the esophagus (14.5 [9.7; 19.3] vs 10.3 [5.6; 14.9]; p = 0.028) and higher DeMeester index values (35.4 [1.9; 114.5] vs 15.1 [0.2; 47.7]; p = 0.004). Conclusion. GERD is a multifactorial disease with a primary impairment of the motor function of the upper gastrointestinal tract. The acidic reflux may affect the development of the intestinal type of epithelial metaplasia.


  • Open Access

    The Effect of Combined Therapy with a Proton Pump Inhibitor and Rebamipide on the Clinical Course and Morphofunctional Changes of the Esophageal Mucosa in Patients with Non-Erosive Reflux Disease

    by A. A. Makushina, A. S. Trukhmanov, A. B. Ponomarev, O. A. Storonova, A. V. Paraskevova, P. G. Ermishina, V. A. Mironova, V. T. Ivashkin

    Aim: to evaluate the effect of combined therapy with a proton pump inhibitor and rebamipide on clinical manifestations and morphofunctional changes in the esophageal mucosa in patients with non-erosive reflux disease.Materials and methods. The study included 39 patients with non-erosive reflux disease randomized into the main group (omeprazole 20 mg/day + rebamipide 300 mg/day) and the comparison group (omeprazole 20 mg/day). The duration of treatment was 4 weeks. Histological examination of esophageal mucosa biopsies (hematoxylin-eosin staining), morphometry of intercellular spaces, and immunohistochemical assessment of tight junction protein expression (claudin-1, -4, occludin) were performed. Symptoms were evaluated using the Likert scale.Results. The combined therapy group showed significant reductions in heartburn severity (p < 0.001) and belching (p = 0.004), with absent/mild symptoms in 63.7 and 72.4 % of patients, respectively. In the proton pump inhibitor monotherapy group, 53 % of patients retained moderate or severe heartburn. Morphologically, the combined group demonstrated reduced eosinophilic infiltration (p = 0.030). Occludin expression increased in both groups but reached statistical significance only in the monotherapy group (p = 0.046).Conclusion. The combined therapy with proton pump inhibitor and rebamipide improves symptoms and morphological outcomes in non-erosive reflux disease. Increased occludin expression suggests restored integrity of intercellular junctions. Further studies with larger cohorts and extended follow-up are needed to confirm these findings.


  • Changes in esophageal functional state during combined acid-suppressive and epithelial protective therapy in patients with non-erosive reflux disease

    by A.A. Makushina, A.S. Trukhmanov, O.A. Storonova, A.V. Paraskevova, P.G. Ermishina, V.A. Mironova, V.T. Ivashkin

    Objective. To evaluate the effect of combination therapy with rebamipide and proton pump inhibitor (PPI) on the functional state of the esophagus in patients with non-erosive reflux disease (NERD). Patients and methods. The study included 60 patients, 39 of whom had a confirmed diagnosis of NERD and were randomized into two groups: the study group receiving combination therapy with rebamipide (300 mg/day) and omeprazole (20 mg/day), and the comparison group receiving omeprazole monotherapy (20 mg/day). The study also included 13 patients with functional heartburn and 8 patients with esophageal hypersensitivity, who were divided into two groups. The duration of treatment was four weeks. To assess the functional state of the esophagus and gastroesophageal junction, as well as the esophageal mucosal resistance, the values of esophageal 24-hour pH-impedance testing and high-resolution manometry before and after treatment were analyzed. Results. In patients with NERD receiving combination therapy, the percentage of time with pH <4 was statistically significantly lower in the follow-up examination after the end of treatment and withdrawal of medications compared to the period before treatment (p = 0.048). In patients receiving PPI monotherapy, no statistically significant changes in the percentage of time with pH <4 were found in the dynamics (p = 0.465). There were statistically significant differences in lower esophageal sphincter pressure between two groups after treatment (p = 0.017). However, analyzing this parameter within each group before and after treatment revealed no statistically significant changes in lower esophageal sphincter pressure. In patients with esophageal hypersensitivity and functional heartburn, changes in the values of esophageal 24-hour pH-impedance testing and highresolution manometry before and after treatment did not reach statistical significance in any of the examined groups. Conclusion. The use of combination therapy with PPI and rebamipide is a safe and effective method to achieve adequate acid suppression, including in the post-treatment period. This therapeutic approach may improve esophageal motility and the state of lower esophageal sphincter. Key words: proton pump inhibitors, non-erosive reflux disease, epithelial protective therapy


  • Open Access

    The Role of Duodenogastroesophageal Reflux in the Progression of Gastroesophageal Reflux Disease: From Esophagitis to Adenocarcinoma

    by O. A. Storonova, A. V. Paraskevova, A. A. Makushina

    Aim: to present data on the role of bile acids in the progression of Barrett's esophagus (BE) and the development of esophageal dysplasia and adenocarcinoma and to provide a rationale for the use of ursodeoxycholic acid in addition to basic therapy in patients with gastroesophageal reflux disease (GERD).Key points. The prevalence of GERD in the world is 13.98 %. In the absence of the necessary treatment or non-compliance with the recommended regimens and duration of drug use, complications of GERD develop such as stricture, bleeding, BE, which, in turn, is a risk factor for the development of esophageal adenocarcinoma (EAC). The basic therapy for GERD is proton pump inhibitors (PPIs), but up to 40 % of patients do not fully respond to PPI monotherapy, which indicates the need to consider, among the factors in the pathogenesis of GERD, the persistence of weakly acidic and weakly alkaline refluxes, the presence of which can be diagnosed by performing 24-hour impedance-pH monitoring. It has been proven that refluxate is predominantly acidic in nature in 50 % of patients with GERD, acidic with a bile component in 39.7 %, and 10.3 % of patients have bile reflux. The weaklly alkaline nature of reflux, due to the presence of duodenal contents, significantly increases the incidence of intestinal metaplasia with dysplasia and EAC compared to acidic pH values. Therefore, stopping duodenal reflux may be an important step in preventing the development of EAC. Among the components of duodenal contents that have a damaging effect on the mucous membrane of the esophagus, the role of bile acids has been most studied. The presence of hydrophobic bile acids, namely deoxycholic acid (DCA), is associated with oxidative DNA damage in lesions of intestinal-type columnar cell metaplasia. Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, is a natural competitive inhibitor of DCA and prevents DNA damage and nuclear factor-κB (NF-κB) activation caused by toxic bile acids in BE epithelial cells. The cytoprotective effect of UDCA, aimed at preventing DNA damage and increasing the reparative capacity of cells in the metaplastic epithelium of the BE, allows us to consider this drug as a means of chemoprophylaxis in patients diagnosed with GERD.Conclusion. The addition of UDCA drugs to the basic therapy is pathogenetically justified in patients with GERD in the presence of duodenogastroesophageal reflux. Prescribing complex therapy will reduce the incidence of esophagitis, progression of BE with the development of dysplasia and adenocarcinoma caused by exposure to bile acids.


  • Eosinophilic esophagitis: clinical presentation, current aspects of diagnosis and treatment

    by A.V. Paraskevova, A.S. Trukhmanov, T.L. Lapina, S.S. Pirogov, A.S. Tertychny, O.A. Storonova, A.A. Makushina, V.T. Ivashkin

  • Open Access

    Efficacy of Topical Corticosteroid Monotherapy in Inducing and Maintaining Clinical and Histologic Remission in Adolescent and Adult Patients with Eosinophilic Esophagitis: a Systematic Review and Meta-Analysis

    by A. A. Makushina, O. A. Storonova, A. S. Trukhmanov, T. L. Lapina, V. T. Ivashkin

    Background: Eosinophilic esophagitis (EoE) is the second most common cause of esophagitis. Topical steroids represent a promising group of drugs for inducing and maintaining clinical and histological remission in these patients.Objective. To evaluate the effectiveness of topical steroids in inducing and maintaining clinical and histological remission in adolescent and adult patients with EoE.Methods. A systematic literature search using defined keywords was performed up to March 20, 2021 in the MEDLINE / PubMed, EMBASE (Excerpta Medica), and Cochrane Central Register of Controlled Trials, ClinicalTrial.gov databases.Results. 390 patients from 5 studies were included in this systematic review with meta-analysis. The meta-analysis showed that topical steroids, compared with placebo, was more effective in inducing (odds ratio (OR) 75.77; 95 % confidence interval (CI): (21.8; 263.41), p < 0.001) and maintaining complete histological remission (OR 103.65; 95 % CI: (36.05; 298.01), p < 0.001) in patients with EoE. Also, topical steroids significantly relieved disease symptoms compared with placebo in inducing and maintaining clinical remission (OR 4.86; 95 % CI: (1.4; 16.86), p = 0.01) and (OR 11.06; 95 % CI: (4.62; 26.45), p < 0.001) respectively.Conclusions. Topical steroids represent an effective group of drugs for inducing and maintaining histologic and clinical remission in adolescent and adult patients with EoE.


  • Open Access

    Severe Diverticulitis Associated to Clostridioides difficile Infection in a 91 Year Old Patient (Clinical Case)

    by A. A. Makushina, L. N. Androsova, K. B. Puzakov, A. V. Okhlobystin, M. A. Tatarkina, O. S. Shifrin

    Aim. To present a clinical case of a 91-year-old patient with a severe course of diverticulitis combined with the development of Clostridioides difficile-associated disease.Key points. On admission the patient complained of pain in the left iliac region, increased body temperature, constipation and bloating. The medical history showed that constipation increased on the background of prolonged bed rest and discontinuation of psyllium. According to the laboratory and instrumental examinations, the patient had signs of acute diverticulitis, antibacterial therapy was corrected twice, positive dynamics of the condition was noted. However, a few days later, the patient developed a clinic of C. difficile-associated disease, which required the prescription of anticlostridial therapy (vancomycin), until the laboratory confirmation of the accession of this infection was obtained. Combined therapy of exacerbation of diverticular disease and C. difficile-associated disease made it possible to achieve a steady improvement of the condition.Conclusion. The exclusion of possible development of C. difficile-associated disease on the background or prior antibiotic therapy is an important condition for correct and adequate management of a patient with exacerbation of diverticular disease. If the patient develops a clinical picture of C. difficile-associated disease, treatment may be initiated before laboratory confirmation.